FY2025 EPS Estimate for TG Therapeutics Increased by Analyst

TG Therapeutics, Inc. (NASDAQ:TGTX) – Analysts at HC Wainwright increased their FY2025 EPS estimates for shares of TG Therapeutics in a research report issued on Wednesday, January 14th. HC Wainwright analyst E. Bodnar now forecasts that the biopharmaceutical company will post earnings per share of $2.89 for the year, up from their previous forecast of $2.83. HC Wainwright has a “Buy” rating and a $60.00 price target on the stock. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for TG Therapeutics’ Q4 2026 earnings at $0.47 EPS, FY2026 earnings at $1.28 EPS, FY2028 earnings at $2.38 EPS, FY2029 earnings at $3.02 EPS and FY2030 earnings at $3.96 EPS.

TGTX has been the topic of several other reports. B. Riley upgraded shares of TG Therapeutics to a “strong-buy” rating in a report on Tuesday, November 4th. Wall Street Zen upgraded TG Therapeutics from a “hold” rating to a “buy” rating in a report on Sunday, December 14th. JPMorgan Chase & Co. upped their price objective on TG Therapeutics from $46.00 to $49.00 and gave the stock an “overweight” rating in a research note on Monday, November 3rd. Weiss Ratings reiterated a “hold (c+)” rating on shares of TG Therapeutics in a report on Monday, December 29th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of TG Therapeutics in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $50.75.

TG Therapeutics Trading Down 0.5%

Shares of NASDAQ TGTX opened at $30.57 on Thursday. TG Therapeutics has a twelve month low of $25.28 and a twelve month high of $46.48. The company has a quick ratio of 2.89, a current ratio of 3.82 and a debt-to-equity ratio of 0.40. The business has a fifty day simple moving average of $30.77 and a two-hundred day simple moving average of $32.53. The firm has a market cap of $4.85 billion, a PE ratio of 11.00 and a beta of 1.86.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Monday, November 3rd. The biopharmaceutical company reported $2.43 EPS for the quarter, topping analysts’ consensus estimates of $0.24 by $2.19. The business had revenue of $161.71 million for the quarter, compared to analyst estimates of $152.12 million. TG Therapeutics had a net margin of 84.13% and a return on equity of 133.24%. The company’s quarterly revenue was up 92.7% compared to the same quarter last year. During the same period last year, the company posted $0.02 earnings per share.

Insiders Place Their Bets

In other TG Therapeutics news, Director Yann Echelard sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $32.57, for a total transaction of $162,850.00. Following the transaction, the director owned 223,816 shares in the company, valued at approximately $7,289,687.12. This represents a 2.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 10.64% of the company’s stock.

Hedge Funds Weigh In On TG Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TGTX. Ameritas Advisory Services LLC acquired a new stake in shares of TG Therapeutics during the second quarter worth about $25,000. Johnson Financial Group Inc. acquired a new stake in shares of TG Therapeutics in the second quarter worth $25,000. Danske Bank A S purchased a new position in shares of TG Therapeutics during the third quarter worth $25,000. Optiver Holding B.V. boosted its holdings in TG Therapeutics by 3,485.7% in the third quarter. Optiver Holding B.V. now owns 753 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 732 shares during the last quarter. Finally, Bessemer Group Inc. grew its position in TG Therapeutics by 117.1% during the 3rd quarter. Bessemer Group Inc. now owns 901 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 486 shares during the period. Hedge funds and other institutional investors own 58.58% of the company’s stock.

Key Stories Impacting TG Therapeutics

Here are the key news stories impacting TG Therapeutics this week:

• Positive Sentiment: Seeking Alpha published an upgrade/positive piece that highlights accelerating commercial momentum and investor “exit velocity,” supporting a more bullish growth narrative for TG Therapeutics. TG Therapeutics: The ‘Exit Velocity’ You Can’t Ignore (Rating Upgrade)
• Positive Sentiment: Media reported that Goldman Sachs sees substantial upside (~32% rally potential) as Briumvi sales accelerate, which supports a bullish case for continued revenue and earnings upside. TG Therapeutics stock pops as Briumvi boom reignites bull case: Goldman Sachs sees room for 32% rally
• Positive Sentiment: HC Wainwright raised its Q4 2025 EPS estimate to $0.27 (from $0.20) and keeps a “Buy” rating with a $60 target — a clear near‑term analyst endorsement that can support upside. MarketBeat TGTX analyst note
• Positive Sentiment: HC Wainwright also raised FY2025 EPS to $2.89 (from $2.83), reflecting stronger near‑term earnings expectations tied to current product momentum. MarketBeat TGTX analyst note
• Neutral Sentiment: HC Wainwright published a set of long‑range forecasts (FY2026–FY2030, including FY2030 EPS of $3.96). These long‑horizon numbers frame upside potential but are model‑dependent and less immediately market‑moving. MarketBeat TGTX analyst note
• Negative Sentiment: Bank of America Securities initiated/maintained a “Sell” on TGTX, which is directly bearish and likely pressured the stock amid mixed optimism elsewhere. TG Therapeutics (TGTX) Receives a Sell from Bank of America Securities
• Negative Sentiment: HC Wainwright trimmed several mid‑to‑longer‑term estimates (Q4 2026, FY2026–FY2029, FY2028–FY2029 down slightly), signaling some moderation in the firm’s prior growth assumptions and reducing upside in those years despite the persistent $60 target. MarketBeat TGTX analyst note

About TG Therapeutics

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.